Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SEPN by emailGet an email when SEPN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SEPN, unsubscribe in one click. Privacy
📣 What SEPN Says Is Next
first quarter of 2027 · “As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027. o During the quarter, the Company presented the first detailed preclinical characterization of SEP-479 in an oral presentation at ENDO 2026, highlighting data supporting its potential as a differentiated, once-daily oral treatment for hypoparathyroidism.”
Company press release, Aug 10, 2026 · SEC filing
late 2026 · “The single-ascending dose and multiple-ascending dose study is evaluating safety, tolerability, pharmacokinetics and pharmacodynamics (including serum calcium and endogenous serum PTH) in healthy volunteers, with data expected in late 2026 or early 2027.”
Company press release, May 11, 2026 · SEC filing
late 2026 · “Septerna anticipates reporting data from the trial in late 2026 or early 2027.”
Company press release, Apr 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SEPN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SEPN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.